INNOCAN PHARMA Corp
INNPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $43 | $75 | $52 | $140 |
| - Cash | $5 | $4 | $5 | $11 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $38 | $71 | $47 | $129 |
| Revenue | $29 | $14 | $3 | $0 |
| % Growth | 115.5% | 433.7% | 1,205.6% | – |
| Gross Profit | $26 | $12 | $2 | $0 |
| % Margin | 89% | 87.7% | 82.3% | 61.7% |
| EBITDA | -$1 | -$4 | -$4 | -$7 |
| % Margin | -4.1% | -27.6% | -144.5% | -3,761% |
| Net Income | -$2 | -$5 | -$4 | -$10 |
| % Margin | -6.2% | -34.4% | -147.1% | -5,126% |
| EPS Diluted | -0.42 | -1.19 | -0.982 | -2.906 |
| % Growth | 64.7% | -21.2% | 66.2% | – |
| Operating Cash Flow | -$2 | -$4 | -$6 | -$7 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$2 | -$4 | -$6 | -$7 |